ADC Therapeutics to Present at November Investor Conferences

Group 1 - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) and is advancing proprietary ADC technology for treating hematologic malignancies and solid tumors [2][3] - The company will participate in two investor conferences in November 2024, with CEO Ameet Mallik presenting at both events [1] - ZYNLONTA, ADC Therapeutics' CD19-directed ADC, has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [3] Group 2 - The investor conferences are scheduled for November 11 and November 19, 2024, with live webcasts available on the company's website [1] - ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development, indicating a robust pipeline [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [4]